ROR1 and cancer: Our results describe the anti-proliferative and anti-metastatic potential of strictinin as an anti-TNBC agent and underlines the intersection of the ROR1/P13K/AKT/GSK3ß pathway as a target for the development of “multi-front” cancer therapies.